Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
0.5186
-0.0051 (-0.97%)
At close: Mar 18, 2026, 4:00 PM EDT
0.5254
+0.0068 (1.31%)
After-hours: Mar 18, 2026, 7:04 PM EDT
Onconetix Revenue
In the year 2025, Onconetix had annual revenue of $815.37K, down -67.70%. Onconetix had revenue of $303.60K in the quarter ending December 31, 2025, a decrease of -57.36%.
Revenue (ttm)
$815.37K
Revenue Growth
-67.70%
P/S Ratio
2.27
Revenue / Employee
$163,074
Employees
5
Market Cap
1.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 815.37K | -1.71M | -67.70% |
| Dec 31, 2024 | 2.52M | 2.47M | 4,217.31% |
| Dec 31, 2023 | 58.47K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.79M |
| Ensysce Biosciences | 4.49M |
| 60 Degrees Pharmaceuticals | 1.36M |
| Scinai Immunotherapeutics | 1.15M |
| BioRestorative Therapies | 383.40K |
| Azitra | 7.50K |
ONCO News
- 4 weeks ago - Onconetix, Inc. (ONCO) M&A Call Transcript - Seeking Alpha
- 4 weeks ago - Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company - GlobeNewsWire
- 4 weeks ago - Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer - Business Wire
- 6 months ago - Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. - GlobeNewsWire
- 6 months ago - Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement - GlobeNewsWire
- 6 months ago - Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM - GlobeNewsWire
- 8 months ago - Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement - GlobeNewsWire
- 9 months ago - Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewsWire